Phase I clinical trial - VADS

Essai clinique fermé
Public cible
A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability,;Pharmacokinetics, and Preliminary Efficacy of ABBV-368 plus Tilsotolimod and Other Therapy;Combinations in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Description de l'essai

The main objective of this study is to assess safety, tolerability, and pharmacokinetics (PK) of ABBV-368 plus tilsotolimod; ABBV-368 plus tilsotolimod and nab-paclitaxel; and ABBV-368 plus tilsotolimod, nab-paclitaxel, and ABBV-181 in participants with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).